BJUI Mini Reviews - Genetic Polymorphism and Pathogenesis of Benign Prostatic Hyperplasia
This review explores additional options for patients with moderate to severe symptomatic BPH, including the administration of α-adrenoceptor blockers (e.g. alfuzosin, tamsulosin) and 5α-reductase inhibitors (e.g. finasteride, dutasteride).
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence
Privacy Policy | © 2010 UroToday ® All Rights Reserved |
